{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(2)"],"submitter":["Hsu YR"],"pubmed_abstract":["<h4>Introduction</h4>Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients with lung adenocarcinoma. However, CEACAM5 expression has not been systematically examined in a real-world and large patient population with NSCLC. There are also limited data on the prognostic impact of CEACAM5 protein expression.<h4>Methods</h4>We assessed CEACAM5 protein expression by immunohistochemistry in two separate cohorts of patients with NSCLC to include both routine clinical biopsy and resection specimens, using the anti-CEACAM5 clone 769 antibody assay protocol and scoring scheme for the tusamitamab ravtansine clinical trials. Expression levels were catego"],"journal":["JTO clinical and research reports"],"pagination":["100943"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828397"],"repository":["biostudies-literature"],"pubmed_title":["The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC."],"pmcid":["PMC12828397"],"pubmed_authors":["Hou L","Azaizeh A","Bates M","Hsu YR","Almutrafi A","Li Q","Tsao MS","Pham NA","Hueniken K"],"additional_accession":[]},"is_claimable":false,"name":"The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC.","description":"<h4>Introduction</h4>Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients with lung adenocarcinoma. However, CEACAM5 expression has not been systematically examined in a real-world and large patient population with NSCLC. There are also limited data on the prognostic impact of CEACAM5 protein expression.<h4>Methods</h4>We assessed CEACAM5 protein expression by immunohistochemistry in two separate cohorts of patients with NSCLC to include both routine clinical biopsy and resection specimens, using the anti-CEACAM5 clone 769 antibody assay protocol and scoring scheme for the tusamitamab ravtansine clinical trials. Expression levels were catego","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-16T04:47:12.023Z","creation":"2026-06-16T03:06:45.383Z"},"accession":"S-EPMC12828397","cross_references":{"pubmed":["41584721"],"doi":["10.1016/j.jtocrr.2025.100943"]}}